References
Pisoni R, Ruggenenti P, Remuzzi G. Renoprotective therapy in patients with nondiabetic nephropathies. Drugs 2001: 61 (6): 733–45
Incidence and prevalence of ESRD. United States Renal Data System. Am J Kidney Dis 1998; 32 (2 Suppl. 1): S38–49
Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15
GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–63
Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Modification of Diet in Renal Disease. Ann Intern Med 1995; 123: 754–62
Mallick NP, Short CD, Hunt LP. How far since Ellis? Nephron 1987; 46: 113–24
Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267–73
Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45
Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999; 10: 997–1006
Ruggenenti P, Perna A, Zoccali C, et al. Chronic proteinuric nephropathies. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to ACE gene polymorphism. J Am Soc Nephrol 2000; 11: 88–96
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Arch Intern Med 2000; 160: 685–93
Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889–96
Zoccali C, Valvo E, Russo D, et al. Antiproteinuric effect of losartan in patients with chronic renal diseases [letter]. Nephrol Dial Transplant 1997; 12: 234–5
Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851–6
Bakris GL, Weir MR, De Quattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–9
Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9: 2308–17
Rights and permissions
About this article
Cite this article
ACE inhibitors still pivotal in the management of proteinuric nephropathies. Drugs Ther. Perspect 18, 8–11 (2002). https://doi.org/10.2165/00042310-200218020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200218020-00004